STERIS Plc (Ireland) 10-Q 9 Aug 16 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information Document - shares	3 Months Ended
	Jun. 30, 2016	Jul. 29, 2016
Entity Information [Line Items]
Entity Registrant Name	STERIS plc
Entity Central Index Key	1,624,899
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Amendment Flag	false
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		86,148,639

CONSOLIDATED BALANCE SHEETS (un

CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Jun. 30, 2016	Mar. 31, 2016
Current assets:
Cash and cash equivalents	$ 242,423	$ 248,841
Accounts receivable (net of allowances of $9,420 and $11,185 respectively)	439,845	471,523
Inventories, net	209,645	192,792
Prepaid expenses and other current assets	53,972	59,369
Total current assets	945,885	972,525
Property, plant, and equipment, net	1,055,706	1,064,319
Intangible Assets, Net (Including Goodwill)	3,258,546	3,279,942
Other assets	33,034	29,630
Total assets	5,293,171	5,346,416
Current liabilities:
Accounts payable	123,253	139,572
Accrued income taxes	14,882	13,683
Accrued payroll and other related liabilities	70,523	93,976
Accrued expenses and other	150,802	153,375
Total current liabilities	359,460	400,606
Long-term indebtedness	1,551,838	1,567,796
Deferred income taxes, net	250,932	254,824
Other Liabilities, Noncurrent	82,456	84,298
Total liabilities	2,244,686	2,307,524
Commitments and contingencies (see note 9
Preferred Stock, Value, Issued	15	15
Common shares, with GBP 0.10 par value; GBP 17,006 shares in the aggregate par amount authorized; 86,151 shares issued; and 85,920 shares outstanding	2,161,050	2,151,719
Retained earnings	961,924	939,459
Accumulated other comprehensive income	(85,718)	(68,159)
Total shareholders' equity	3,037,271	3,023,034
Noncontrolling interest	11,214	15,858
Total equity	3,048,485	3,038,892
Total liabilities and equity	$ 5,293,171	$ 5,346,416

CONSOLIDATED BALANCE SHEETS (u3

CONSOLIDATED BALANCE SHEETS (unaudited) Consolidated Balance Sheet (Parenthetical) $ in Thousands	3 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2016£ / shares	Jun. 30, 2016USD ($)$ / sharesshares	Mar. 31, 2016USD ($)$ / sharesshares
Allowance for Doubtful Accounts Receivable, Current | $			$ 9,420	$ 11,185
Preferred Stock, Shares Authorized			100,000	100,000
Preferred Stock, Shares Issued			100,000	100,000
Preferred Stock, Shares Outstanding			100,000	100,000
Preferred Stock, Par or Stated Value Per Share | $ / shares			$ 0.10	$ 0.15
common stock aggregate par amount shares authorized | $	$ 17,006
Common Stock, Shares Authorized, Unlimited				170,060,000
Common Stock, Shares, Issued			86,151,000	85,920,000
Common Stock, Shares, Outstanding			86,151,000	85,920,000
Common Stock, Par or Stated Value Per Share | (per share)		£ 0.10		$ 0.15
Treasury Stock, Shares			0	0

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Revenues:
Product	$ 271,750	$ 232,307
Service	366,628	207,595
Total revenues	638,378	439,902
Cost of revenues:
Product	142,698	129,856
Service	255,690	125,956
Total cost of revenues	398,388	255,812
Gross Profit	239,990	184,090
Operating expenses:
Selling, general, and administrative	151,886	126,835
Research and development	14,428	13,765
Restructuring expenses	154	(449)
Restructuring Costs	154	(726)
Total operating expenses	166,468	139,874
Income (loss) from operations	73,522	44,216
Non-operating expenses, net:
Interest expense	11,071	6,120
Interest income and miscellaneous expense	(493)	(482)
Total non-operating expenses, net	10,578	5,638
Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest	62,944	38,578
Income tax expense (benefit)	(14,234)	(14,267)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	48,710	24,311
Net Income (Loss) Attributable to Noncontrolling Interest	309	20
Net (loss) income	$ 48,401	$ 24,291
Net income (loss) per common share
Basic	$ 0.56	$ 0.41
Diluted	0.56	0.40
Cash dividends declared per common share outstanding	$ 0.25	$ 0.23

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Other Comprehensive Income (Loss), Available-for-sale Securities, Tax	$ 34	$ 226
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	48,710	24,311
Net Income (Loss) Attributable to Noncontrolling Interest	309	20
Net Income (Loss) Attributable to Parent	48,401	24,291
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	(120)	(848)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Unamortized Gain (Loss) Arising During Period, Net of Tax	(390)	(153)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	(17,049)	13,798
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(17,559)	12,797
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	30,842	37,088
Other Comprehensive (Income) Loss, Amortization Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax	$ 241	$ 95

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Net Income (Loss) Attributable to Parent	$ 48,401,000	$ 24,291,000
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	48,710,000	24,311,000
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation, depletion, and amortization	53,784,000	22,353,000
Deferred income taxes	989,000	5,629,000
Share-based compensation	4,187,000	3,145,000
Loss on the disposal of property, plant, equipment, and intangibles, net	126,000	3,000
Excess Tax Benefit from Share-based Compensation, Operating Activities	0	(3,910,000)
Other items	(17,713,000)	(19,838,000)
Changes in operating assets and liabilities:
Accounts receivable, net	23,248,000	38,869,000
Inventories, net	(19,765,000)	(18,174,000)
Other current assets	3,687,000	463,000
Accounts payable	(13,246,000)	(5,696,000)
Accruals and other, net	(3,691,000)	(6,002,000)
Net cash provided by operating activities	80,316,000	41,153,000
Investing activities:
Purchases of property, plant, equipment, and intangibles, net	(35,357,000)	(23,518,000)
Proceeds from the sale of property, plant, equipment, and intangibles	4,526,000	28,000
Payments to Acquire Investments	(4,564,000)	0
Other Payments to Acquire Businesses	(250,000)	(44,310,000)
Net cash used in investing activities	(35,645,000)	(67,800,000)
Financing activities:
Proceeds from Issuance of Private Placement	0	350,000,000
Repayments of Long-term Debt	(5,000,000)	0
Proceeds Under Credit Facility, net	(11,079,000)	(283,250,000)
Payments of Financing Costs	0	(1,978,000)
Payments of Merger Related Costs, Financing Activities	(6,000,000)	0
Repurchases of common shares	(5,171,000)	(9,573,000)
Cash dividends paid to common shareholders	(21,538,000)	(13,758,000)
Proceeds from Issuance or Sale of Equity	5,022,000	0
Stock option and other equity transactions, net	758,000	4,881,000
Excess Tax Benefit from Share-based Compensation, Financing Activities	0	3,910,000
Net cash used in financing activities	(43,008,000)	50,232,000
Effect of exchange rate changes on cash and cash equivalents	(8,081,000)	4,919,000
(Decrease) increase in cash and cash equivalents	(6,418,000)	28,504,000
Cash and cash equivalents at beginning of period	248,841,000	167,689,000
Cash and cash equivalents at end of period	$ 242,423,000	$ 196,193,000

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Nature of Operations [Text Block]	Nature of Operations and Summary of Significant Accounting Policies Nature of Operations STERIS plc, a public limited company organized under the laws of England and Wales, was incorporated on October 9, 2014 as a private limited company under the name New STERIS Limited and was re-registered effective November 2, 2015 as a public limited company under the name STERIS plc. New STERIS Limited was established to effect the combination (“Combination”) of STERIS Corporation, an Ohio corporation (“Old STERIS”), and Synergy Health plc, a public limited company organized under the laws of England and Wales (“Synergy”). The Combination closed on November 2, 2015 and as a result STERIS plc became the ultimate parent company of Old STERIS and Synergy. Synergy has been re-registered under the name Synergy Health Limited. The acquisition of Old STERIS was accounted for in the consolidated financial statements as a merger between entities under common control; accordingly the historical consolidated financial statements of Old STERIS for periods prior to November 2, 2015, are considered to be the historical financial statements of STERIS plc. Due to the timing of the Combination, the results of Synergy are only reflected in the results of operations of the Company from November 2, 2015 forward which affects comparability to the prior period historical operations of the Company throughout this Quarterly Report on Form 10-Q. STERIS offers Customers capital equipment products, such as sterilizers and surgical tables; connectivity solutions such as operating room integration; consumable products, such as detergents, gastrointestinal endoscopy accessories, barrier product solutions, and other products and services, including: equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair solutions, among other services. Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below: Interim Financial Statements We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented. These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended March 31, 2016 dated May 31, 2016 . The Consolidated Balance Sheet at March 31, 2016 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Principles of Consolidation We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements. In prior periods we presented income attributable to noncontrolling interests in the "Interest income and miscellaneous expense" line of our Consolidated Statements of Income and the amounts were not material. Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three month period ended June 30, 2016 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2017 . Recently Issued Accounting Standards Impacting the Company Recently issued accounting standards impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have recently been adopted ASU 2015-05, "Goodwill and other-Internal-Use Software" (Subtopic 350-40) April 2015 The standard provides guidance on a customer's accounting for fees paid in cloud computing arrangements. Previously, there was no U.S. GAAP guidance on accounting for such fees from the customer's perspective. Under the standard, customers will apply the same criteria as vendors to determine whether the arrangement contains a software license or is solely a service contract. The determination could impact the classification of advance payments in the statements of financial position and cash flows as well as the classification of the expenses in the results of operations. The standard is effective for annual periods beginning after December 15, 2015 and interim periods within that period. Early adoption is permitted. First Quarter Fiscal 2017 The adoption of this standard did not have a material impact on our statements of consolidated financial position, results of operations and cash flows. ASU 2016-09, "Stock Compensation: Improvements to Employee Share-Based Payment Accounting" (Topic 718) March 2016 The update simplifies several aspects of the accounting for share-based payment award transactions, including income tax consequences, the classification of awards as either equity or liabilities, and the classification on the statement of cash flows. The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that period. Early adoption is permitted. First Quarter Fiscal 2017 As a result of the adoption of this standard, we recorded $2.4 million of excess tax benefits associated with share based compensation in the statement of income for the three months ended June 30, 2016 and have included the associated cash flows as cash provided by operating activities. Prior periods have not been restated. Standards that have yet to be adopted ASU 2014-09, "Revenue from Contracts with Customers" May 2014 The standard will replace existing revenue recognition standards and significantly expand the disclosure requirements for revenue arrangements. It may be adopted either retrospectively or on a modified retrospective basis to new contracts and existing contracts with remaining performance obligations as of the effective date. The standard update is effective for annual periods beginning after December 15, 2017 and interim periods within that period, early adoption is not permitted before the original public entity effective date of December 15, 2016. N/A We are currently in the process of evaluating the impact that the standard will have on our consolidated financial position, results of operations and cash flows. ASU 2016-02, "Leases" (Topic 842) February 2016 The update will require lessees to record all leases, whether finance or operating, on the balance sheet. An asset will be recorded to represent the right to use the leased asset, and a liability will be recorded to represent the lease obligation. The standard is effective for annual periods beginning after December 15, 2018 and interim periods within that period. Early adoption is permitted. N/A We are in the process of evaluating the impact that the standard will have on our statements of consolidated financial position, results of operations and cash flows. ASU 2016-07, "Investments - Equity Method and Joint Ventures, Simplifying the Transition to the Equity Method of Accounting" (Topic 323) March 2016 The update replaces the previous requirement to retroactively adopt the equity method. The new standard requires that the equity method investor add the cost of acquiring the additional interest in the investee to the current basis of the investor's previously held interest and adopt the equity method of accounting as of the date the investment becomes qualified for equity method accounting. The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that period. Early adoption is permitted. N/A We do not expect the adoption of this standard to have a material impact on our statements of consolidated financial position, results of operations and cash flows. A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2016 dated May 31, 2016 . Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2016 .

Restructuring

Restructuring	3 Months Ended
	Jun. 30, 2016
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring Fiscal 2014 Restructuring Plan. During the fourth quarter of fiscal 2014, we adopted and announced a targeted restructuring plan primarily focused on the closure of our Hopkins manufacturing facility located in Mentor, Ohio (the “Fiscal 2014 Restructuring Plan”). As a result of this plan, we will transfer operations located at Hopkins to other North American locations. We believe that by closing the operations at Hopkins we will more effectively utilize our existing North American manufacturing network while reducing operating costs. Since the inception of the Fiscal 2014 Restructuring Plan, we have incurred pre-tax expenses totaling $19,128 related to these actions, of which $11,032 was recorded as restructuring expenses and $8,096 was recorded in cost of revenues, with restructuring expenses of $15,726 , $1,293 , $829 , and $1,280 related to the Healthcare Products, Healthcare Specialty Services, Life Sciences and Applied Sterilization Technologies segments, respectively. The following table summarizes our total pre-tax restructuring expenses for the first quarters of fiscal 2017 and fiscal 2016: Three Months Ended June 30, 2016 Fiscal 2014 Restructuring Plan Lease termination obligation and other $ 154 Total restructuring charges $ 154 Three Months Ended June 30, 2015 Fiscal 2014 Restructuring Plan (1) Severance and other compensation related costs $ (806 ) Lease termination obligation and other 80 Product rationalization 277 Total restructuring benefit $ (449 ) (1) Includes $277 in expense recorded to cost of revenues on Consolidated Statements of Income. Liabilities related to restructuring activities were $688 and $700 at June 30, 2016 and March 31, 2016, respectively and are recorded as current liabilities on the accompanying Consolidated Balance Sheets within “Accrued payroll and other related liabilities” and “Accrued expenses and other.”

Property, Plant and Equipment

Property, Plant and Equipment	3 Months Ended
	Jun. 30, 2016
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment	Property, Plant and Equipment Information related to the major categories of our depreciable assets is as follows: June 30, March 31, Land and land improvements (1) $ 39,054 $ 39,051 Buildings and leasehold improvements 443,234 446,277 Machinery and equipment 574,277 580,962 Linens 42,291 42,354 Information systems 131,487 126,180 Radioisotope 434,189 434,152 Construction in progress (1) 89,692 79,291 Total property, plant, and equipment 1,754,224 1,748,267 Less: accumulated depreciation and depletion (698,518 ) (683,948 ) Property, plant, and equipment, net $ 1,055,706 $ 1,064,319 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Inventories, Net

Inventories, Net	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Inventories, Net	Inventories, Net Inventories, net are stated at the lower of cost or market. We use the last-in, first-out (“LIFO”) and first-in, first-out cost methods. An actual valuation of inventory under the LIFO method is made only at the end of the fiscal year based on the inventory levels and costs at that time. Accordingly, interim LIFO calculations are based on management’s estimates of expected year-end inventory levels and are subject to the final fiscal year-end LIFO inventory valuation. Inventory costs include material, labor, and overhead. Inventories, net consisted of the following: June 30, March 31, Raw materials $ 67,374 $ 62,673 Work in process 22,192 19,614 Finished goods 156,236 146,820 LIFO reserve (17,270 ) (17,608 ) Reserve for excess and obsolete inventory (18,887 ) (18,707 ) Inventories, net $ 209,645 $ 192,792

Debt

Debt	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Debt	Debt Indebtedness was as follows: June 30, March 31, Private Placement $ 666,000 $ 666,000 Deferred financing costs (3,299 ) (3,420 ) Credit Agreement 889,137 905,216 Total long term debt $ 1,551,838 $ 1,567,796 Additional information regarding our indebtedness is included in the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2016 dated May 31, 2016 .

Additional Consolidated Balance

Additional Consolidated Balance Sheets Information	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Additional Consolidated Balance Sheets Information	Additional Consolidated Balance Sheet Information Additional information related to our Consolidated Balance Sheets is as follows: June 30, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 37,685 $ 30,175 Accrued vacation/paid time off 12,070 14,368 Accrued bonuses 8,679 31,502 Accrued employee commissions 8,727 13,809 Other postretirement benefit obligations-current portion 2,463 2,463 Other employee benefit plans obligations-current portion 899 1,659 Total accrued payroll and other related liabilities $ 70,523 $ 93,976 Accrued expenses and other: Deferred revenues $ 64,205 $ 56,238 Self-insured risk reserves-current portion 8,294 8,266 Accrued dealer commissions 13,982 12,717 Accrued warranty 5,856 5,909 Other 58,465 70,245 Total accrued expenses and other $ 150,802 $ 153,375 Other liabilities: Self-insured risk reserves-long-term portion $ 13,257 $ 13,257 Other postretirement benefit obligations-long-term portion 15,621 15,932 Defined benefit pension plans obligations-long-term portion 23,221 25,301 Other employee benefit plans obligations-long-term portion 4,186 4,366 Asset retirement obligation-long-term portion 10,059 10,342 Other 16,112 15,100 Total other liabilities $ 82,456 $ 84,298

Income Tax Expense (Benefit)

Income Tax Expense (Benefit)	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Income Tax Expense (Benefit)	Income Tax Expense Income tax expense includes United States federal, state and local, and foreign income taxes, and is based on reported pre-tax income. The effective income tax rates for the three-month periods ended June 30, 2016 and 2015 were 22.6% and 37.0% , respectively. The first quarter of fiscal 2017 was favorably impacted by benefits achieved in conjunction with the Synergy transaction and the adoption of ASU 2016-09: "Stock Compensation: Improvements to Employee Share-Based Payment Accounting" (Topic 718). Income tax expense is provided on an interim basis based upon our estimate of the annual effective income tax rate, adjusted each quarter for discrete items. In determining the estimated annual effective income tax rate, we analyze various factors, including projections of our annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives. We operate in numerous taxing jurisdictions and are subject to regular examinations by various United States federal, state and local authorities, as well as foreign jurisdictions. We are no longer subject to United States federal examinations for years before fiscal 2013 and, with limited exceptions, we are no longer subject to United States state and local or non-United States income tax examinations by tax authorities for years before fiscal 2012. We remain subject to tax authority audits in various jurisdictions wherever we do business. We do not expect the results of these examinations to have a material adverse affect on our consolidated financial statements.

Benefit Plans

Benefit Plans	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Benefit Plans	Benefit Plans In the United States we sponsor an unfunded postretirement welfare benefits plan for two groups of former employees. Benefits under this plan include retiree life insurance and retiree medical coverage, including prescription drug coverage. During the second quarter of fiscal 2009, we amended our United States post-retirement welfare benefits plan, reducing the benefits to be provided to retirees under the plan and increasing their share of the costs. The amendments resulted in a decrease of $46,001 in the accumulated post-retirement benefit obligation. The impact of this change was recognized in our Consolidated Balance Sheets in fiscal 2009 and is being amortized as a component of the annual net periodic benefit cost over a period of approximately thirteen years. In July 2014, the Board of Directors of American Sterilizer Company (“AMSCO”) approved the termination of the American Sterilizer Company Retirement Income Plan (“Plan”) effective October 1, 2014. The Pension Benefit Guaranty Corporation ("PBGC") did not object to this termination and AMSCO received a favorable determination from the IRS regarding the termination. On August 19, 2015, an annuity contract was purchased from Massachusetts Mutual Life Insurance Company to provide Plan benefits. Plan assets were converted to cash to fund the purchase. The purchase price of the annuity contract was $51,805 . An additional employer contribution of $4,641 was made to the Plan to fund the annuity purchase obligation on August 26, 2015. As a result the purchase of the annuity, we recognized a pension settlement of $26,470 in fiscal 2016. In addition, plan benefits and benefit administration became the responsibility of the annuity provider. Additional information regarding this defined benefit pension plan and other postretirement benefits plan is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2016, dated May 31, 2016. In the United Kingdom, we sponsor a defined benefit arrangement administered by a single group of trustees. The arrangement is comprised of three merged schemes. The trustees hold the pension assets to meet long-term pension liabilities for past and present employees. The level of retirement benefit is principally based on the terms of the scheme and the final pensionable salary prior to leaving active service, and is linked to changes in inflation up to retirement. In previous years, Synergy sponsored a funded defined benefit arrangement in the Netherlands. This was a separate fund holding the pension scheme assets to meet long term pension liabilities for past and present employees. Accrual of benefits ceased under the scheme effective January 1, 2013. The Synergy Radeberg and Synergy Alleshausen Schemes are German defined benefit funded pension schemes which are closed to new entrants. The Synergy Daniken Scheme is a Swiss defined benefit funded pension scheme. Components of the net periodic benefit cost for our defined benefit pension plans and other postretirement medical benefits plan were as follows: AMSCO Plan Other Defined Benefit Pension Plan Other Postretirement Benefits Plan Three Months Ended June 30, 2016 2015 2016 2015 2016 2015 Service cost $ — $ 16 $ 472 $ — $ — $ — Interest cost — 336 189 — 139 148 Expected return on plan assets — (605 ) — — — — Amortization of loss — 361 — — 184 207 Amortization of prior service cost — — — — (816 ) (815 ) Net periodic benefit cost $ — $ 108 $ 661 $ — $ (493 ) $ (460 ) We contribute amounts to the defined benefit pension plan at least sufficient to meet the minimum requirements as stated in applicable employee benefit laws and local tax laws. We record liabilities for the difference between the fair value of the plan assets and the benefit obligation (the projected benefit obligation for pension plan and the accumulated postretirement benefit obligation for other postretirement benefits plan) on our accompanying Consolidated Balance Sheets. Finally, the Dutch linen business acquired in the Synergy combination participates in a multi-employer industry-wide defined benefit scheme. Participation in this pension plan is mandatory. The pension scheme is an average pay scheme with a conditional fee (indexation). Indexation of assets and liabilities granted under the pension scheme takes place only if and insofar as the resources of the fund allow for it and this decision is taken by the pension fund. The pension entitlements under the pension plan are fully reinsured. It is not possible to identify the share of the underlying assets, liabilities, and overall surplus/deficit of the scheme attributable to the business, because the scheme is industry-wide. Under the guidance provided in ASC 715, "Compensation-Retirement Benefits", the scheme is treated as a defined contribution scheme within our financial statements. The total cost charged to the income statement in respect to this scheme was $661 for the three months ended June 30, 2016.

Contingencies

Contingencies	3 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Loss Contingencies by Contingency [Text Block]	Commitments and Contingencies We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief. We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us. On May 31, 2012, our Albert Browne Limited subsidiary received a warning letter from the FDA regarding chemical indicators manufactured in the United Kingdom. These devices are intended for the monitoring of certain sterilization and other processes. The FDA warning letter states that the agency has concerns regarding operational business processes. We do not believe that the FDA's concerns are related to product performance, or that they result from Customer complaints. We have reviewed our processes with the agency and finalized our remediation measures, and are awaiting FDA reinspection. We do not currently believe that the impact of this event will have a material adverse effect on our financial results. On December 19, 2014, a purported shareholder of Old STERIS filed a Verified Stockholder Derivative Complaint in the Court of Common Pleas, Cuyahoga County, Ohio (the "Court"), against the members of Old STERIS’s board of directors and certain officers of Old STERIS, challenging the excise tax make-whole payments approved by Old STERIS’s board in connection with the Combination. Old STERIS was named as a nominal defendant in the action. The case is captioned St. Lucie County Fire District Firefighters’ Pension Trust Fund v. Rosebrough, Jr., et al. , Case No. CV 14 837749 (the "Action"). On September 28, 2015, the defendants reached an agreement in principle with plaintiff, regarding a settlement of the Action, and that agreement is reflected in a memorandum of understanding. In connection with the contemplated settlement, Old STERIS agreed to make certain additional disclosures related to the make-whole payments, which disclosures were reported on Old STERIS's Form 8-K dated September 28, 2015, and also agreed not to grant any new stock compensation subject to Section 4985 of the Internal Revenue Code to any of the individual defendants in the Action until six months following the closing date of the Combination. The parties have subsequently entered into and executed a stipulation of settlement, on a combined class and derivative basis, including agreement on a maximum fee/expense award to plaintiff's counsel. The stipulation of settlement, which is subject to customary conditions including approval of the Court following notice and hearing, has been filed with the Court along with a request for preliminary approval and the setting of a hearing date. The Court has not yet acted on the request. There can be no assurance that the Court will approve the proposed settlement and the settlement agreement may be terminated if Court approval is not obtained. Other civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially effect our business, performance, prospects, value, financial condition, and results of operations. For additional information regarding these matters, see the following portions of our Annual Report on Form 10-K for the year ended March 31, 2016 dated May 31, 2016: “Business - Information with respect to our Business in General - Government Regulation”, and the “Risk Factor” titled “We may be adversely affected by product liability claims or other legal actions or regulatory or compliance matters. From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized. We are subject to taxation from United States federal, state and local, and foreign jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in note 7 to our consolidated financial statements titled, “Income Taxes” in this Quarterly Report on Form 10-Q. Additional information regarding our contingencies is included in Item 2 titled, “Management’s Discussion and Analysis of Financial Conditions and Results of Operations under "Contingencies".

Business Segment Information

Business Segment Information	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Business Segment Information	Business Segment Information We operate and report in four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. Corporate and other, which is presented separately, contains the Defense and Industrial business unit plus costs that are associated with being a publicly traded company and certain other corporate costs. Our Healthcare Products segment offers infection prevention and procedural solutions for healthcare providers worldwide, including capital equipment and related maintenance and installation services, as well as consumables. Our Healthcare Specialty Services segment provides a range of specialty services for healthcare providers including hospital sterilization services, instrument and scope repairs, and linen management. Our Life Sciences segment offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities. Our Applied Sterilization Technologies segment offers a contract sterilization and laboratory services for medical device and pharmaceutical Customers and others. The accounting policies for reportable segments are the same as those for the consolidated Company. Management evaluates performance and allocates resources based on a segment operating income measure. Operating income (loss) for each segment is calculated as the segment’s gross profit less direct expenses and indirect cost allocations, which result in the full allocation of all distribution and research and development expenses, and the partial allocation of corporate costs. These allocations are based upon variables such as segment headcount and revenues. In addition, the Healthcare Products segment is responsible for the management of all but two manufacturing facilities and uses standard cost to sell products to the other segments. Corporate and other includes the gross profit and direct expenses of the Defense and Industrial business unit, as well as certain unallocated corporate costs related to being a publicly traded company and legacy pension and post-retirement benefits. Segment operating income excludes certain adjustments which include acquisition related costs, amortization of acquired intangibles, restructuring costs and other charges that management believes may or may not recur with similar materiality or impact on operating income in future periods. Management believes that by excluding these items they gain better insight and greater transparency of the operating performance of the segments, thus aiding them in more meaningful financial trend analysis and operational decision making For the three month period ended June 30, 2016 , revenues from a single Customer did not represent ten percent or more of any reportable segment’s revenues. Additional information regarding our segments is included in our consolidated financial statements included in its Annual Report on Form 10-K for the year ended March 31, 2016 , dated May 31, 2016 . Financial information for each of our segments is presented in the following tables: Three Months Ended June 30, 2016 2015 Revenues: Healthcare Products $ 281,298 $ 261,086 Healthcare Specialty Services 157,888 68,241 Life Sciences 81,189 56,772 Applied Sterilization Technologies 116,573 53,689 Corporate and other 1,430 114 Total revenues $ 638,378 $ 439,902 Segment operating income: Healthcare Products $ 34,637 $ 29,350 Healthcare Specialty Services 3,318 3,900 Life Sciences 24,462 13,450 Applied Sterilization Technologies 39,603 16,543 Corporate and other (496 ) (1,898 ) Total segment operating income $ 101,524 $ 61,345 Less: Adjustments Restructuring charges (1) $ 154 $ (449 ) Amortization of acquired intangible assets (2) 19,529 6,021 Acquisition, divestiture and integration related charges (3) 5,233 11,546 Amortization of inventory and property "step up" to fair value (2) 3,086 11 Total operating income $ 73,522 $ 44,216

Common Shares

Common Shares	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Earnings Per Share [Text Block]	We calculate basic earnings per share based upon the weighted average number of shares outstanding. We calculate diluted earnings per share based upon the weighted average number of shares outstanding plus the dilutive effect of share equivalents calculated using the treasury stock method. The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share: Three Months Ended June 30, 2016 2015 Denominator (shares in thousands): Weighted average shares outstanding—basic 86,038 59,768 Dilutive effect of share equivalents 481 518 Weighted average shares outstanding and share equivalents—diluted 86,519 60,286 Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Three Months Ended June 30, 2016 2015 (shares in thousands) Number of share options 364 52 Preferred Shares Pursuant to an engagement letter dated October 23, 2015, we issued 100,000 preferred shares, par value of £0.10 ( $0.15 ) each, for an aggregate consideration of approximately $15 , in satisfaction of debt owed to a service provider. The holders of the preferred shares are entitled to a fixed cumulative preferential annual dividend of 5 percent on the amount paid periodically on the preferred shares respectively held by them. On a return of capital of the Company whether on liquidation or otherwise, the holders of the preferred shares shall be entitled to receive out of the assets of the Company available for distribution to its shareholders the sum of £0.10 ( $0.15 ) per preferred share plus any accrued but unpaid dividend, but will not be entitled to any further participation in the assets of the Company. The holders of the preferred shares will have no right to attend, speak or vote, whether in person or by proxy, at any general meeting of the Company or any meeting of a class of members of the Company in respect of the preferred shares and will not be entitled to receive any notice of meetings.

Repurchases of Common Shares

Repurchases of Common Shares	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Schedule of Treasury Stock by Class [Text Block]	Repurchases of Shares During the first quarter of fiscal 2017, we obtained 104,626 of our ordinary shares in connection with share based compensation award programs.

Share-Based Compensation

Share-Based Compensation	3 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	Share-Based Compensation We maintain a long-term incentive plan that makes available shares for grants, at the discretion of the Compensation Committee of the Board of Directors, to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, stock appreciation rights and share grants. Stock options provide the right to purchase our shares at the market price on the date of grant, subject to the terms of the option plans and agreements. Generally, one-fourth of the stock options granted become exercisable for each full year of employment following the grant date. Stock options granted generally expire 10 years after the grant date, or in some cases earlier if the option holder is no longer employed by us. Restricted shares and restricted share units generally may cliff vest after a four year period or vest in tranches of one-fourth of the number granted for each full year of employment after the grant date. As of June 30, 2016 , 1,613,977 shares remained available for grant under the long-term incentive plan. The fair value of share-based compensation awards was estimated at their grant date using the Black-Scholes-Merton option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable, characteristics that are not present in our option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Income. The expense is classified as cost of goods sold or selling, general and administrative expenses in a manner consistent with the employee’s compensation and benefits. The following weighted-average assumptions were used for options granted during the first three months of fiscal 2017 and fiscal 2016 : Fiscal 2017 Fiscal 2016 Risk-free interest rate 1.29 % 1.46 % Expected life of options 5.5 years 5.6 years Expected dividend yield of stock 1.55 % 1.40 % Expected volatility of stock 22.78 % 24.74 % The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a time frame similar to that of the expected life of the grant. An estimated forfeiture rate of 1.85% and 1.55% was applied in fiscal 2017 and 2016 , respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually. A summary of share option activity is as follows: Number of Options Weighted Average Exercise Price Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at March 31, 2016 1,729,517 $ 44.01 Granted 370,212 69.72 Exercised (18,131 ) 29.95 Forfeited (2,703 ) 59.41 Canceled — — Outstanding at June 30, 2016 2,078,895 $ 48.69 6.7 years $ 42,065 Exercisable at June 30, 2016 1,238,705 $ 38.35 5.2 years $ 37,658 We estimate that 816,670 of the non-vested stock options outstanding at June 30, 2016 will ultimately vest. The aggregate intrinsic value in the table above represents the total pre-tax difference between the $68.75 closing price of our ordinary shares on June 30, 2016 over the exercise prices of the stock options, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes and the value changes daily based on the daily changes in the fair market value of ordinary shares. The total intrinsic value of stock options exercised during the first three months of fiscal 2017 and fiscal 2016 was $727 and $5,582 , respectively. Net cash proceeds from the exercise of stock options were $758 and $4,881 for the first three months of fiscal 2017 and fiscal 2016 , respectively. The weighted average grant date fair value of stock option grants was $13.15 and $14.11 for the first three months of fiscal 2017 and fiscal 2016 , respectively. Stock appreciation rights (“SARS”) carry generally the same terms and vesting requirements as stock options except that they are settled in cash upon exercise and therefore, are classified as liabilities. The fair value of the outstanding SARS as of June 30, 2016 and 2015 was $1,857 and $1,966 , respectively. A summary of the non-vested restricted share activity is presented below: Number of Restricted Shares Number of Restricted Share Units Weighted-Average Grant Date Fair Value Non-vested at March 31, 2016 872,972 41,641 $ 51.98 Granted 219,167 9,390 69.77 Vested (186,856 ) (10,589 ) 38.74 Canceled (10,722 ) (2,275 ) 60.54 Non-vested at June 30, 2016 894,561 38,167 $ 59.02 Restricted shares granted are valued based on the closing stock price at the grant date. The value of restricted shares that vested during the first three months of fiscal 2017 was $7,087 . Restricted share units carry generally the same terms and vesting requirements as restricted stock except that they may be settled in stock or cash upon vesting. Those that are settled in cash are classified as liabilities. All outstanding cash-settled restricted share units vested during fiscal year 2016. The fair value of cash-settled restricted share units are revalued at each reporting date and the related liability and expense are adjusted accordingly. The tax benefit from share-based compensation was $2,440 and $3,910 for the first three months of fiscal 2017 and fiscal 2016 , respectively. As of June 30, 2016 , there was a total of $47,882 in unrecognized compensation cost related to non-vested share-based compensation granted under our share-based compensation plans. We expect to recognize the cost over a weighted average period of 2.45 years.

Financial and Other Guarantees

Financial and Other Guarantees	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Product Warranty Disclosure [Text Block]	Financial and Other Guarantees We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. Changes in our warranty liability during the first three months of fiscal 2017 were as follows: Balance, March 31, 2016 $ 5,909 Warranties issued during the period 2,742 Settlements made during the period (2,795 ) Balance, June 30, 2016 $ 5,856 We also sell product maintenance contracts to our Customers. These contracts range in terms from one to five years and require us to maintain and repair the product over the maintenance contract term. We initially record amounts due from Customers under these contracts as a liability for deferred service contract revenue on the accompanying Consolidated Balance Sheets within “Accrued expenses and other.” The liability recorded for such deferred service revenue was $32,953 and $33,416 as of June 30, 2016 and March 31, 2016 , respectively. Such deferred revenue is then amortized on a straight-line basis over the contract term and recognized as service revenue on our accompanying Consolidated Statements of Income. The activity related to the liability for deferred service contract revenue is excluded from the table presented above.

Forward and Swap Contracts

Forward and Swap Contracts	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	Derivatives and Hedging From time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including inter-company transactions. We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our cost of revenues. We do not use derivative financial instruments for speculative purposes. These contracts are not designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income. At June 30, 2016 , we held foreign currency forward contracts to buy 90.0 million Mexican pesos, 4.0 million British pounds sterling, 3.5 million euros, and 8.0 million Canadian dollars. At June 30, 2016 we held commodity swap contracts to buy 499.0 thousand pounds of nickel. Asset Derivatives Liability Derivatives Balance Sheet Fair Value at Fair Value at Fair Value at Fair Value at Location June 30, 2016 March 31, 2016 June 30, 2016 March 31, 2016 Prepaid & Other $ 351 $ 145 $ — $ — Accrued expenses and other $ — $ — $ 293 $ 122 The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income: Location of gain (loss) recognized in income Amount of gain (loss) recognized in income Three Months Ended June 30, 2016 2015 Foreign currency forward contracts Selling, general and administrative $ (1,019 ) $ 432 Commodity swap contracts Cost of revenues $ 211 $ (45 ) Additionally, we hold our debt in multiple currencies to fund our operations and investments in certain subsidiaries. We designate portions of foreign currency denominated intercompany loans as hedges of portions of net investments in foreign operations. Net debt designated as non-derivative net investment hedging instruments totaled $123,811 at June 30, 2016. These hedges are designed to be fully effective and any associated gain or loss is recognized in Accumulated Other Comprehensive Income and will be reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Fair Value, Measurement Inputs, Disclosure [Text Block]	Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial assets and liabilities using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions. The following table shows the fair value of our financial assets and liabilities at June 30, 2016 and March 31, 2016: Fair Value Measurements at June 30, 2016 and March 31, 2016 Using Carrying Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Level 1 Level 2 Level 3 June 30 March 31 June 30 March 31 June 30 March 31 June 30 March 31 Assets: Cash and cash equivalents (1) $ 242,423 $ 248,841 $ 217,246 $ 225,090 $ 25,177 $ 23,751 $ — $ — Forward and swap contracts (2) 351 145 — — 351 145 — — Investments (3) 10,148 6,192 10,148 6,192 — — — — Liabilities: Forward and swap contracts (2) $ 293 $ 122 $ — $ — $ 293 $ 122 $ — $ — Deferred compensation plans (3) 1,703 1,765 1,703 1,765 — — — — Long term debt (4) 1,551,838 1,567,796 — — 1,601,514 1,592,184 — — Contingent consideration obligations (5) 5,956 5,886 — — — — 5,956 5,886 (1) Money market fund holdings are classified as level two as active market quoted prices are not available. (2) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (3) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Changes in the value of the investment accounts are recognized each period based on the fair value of the underlying investments. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers including an incremental investment of $4,564 made in April 2016. Changes in the value of the investment are recognized each period based on the fair value of the investment. (4) We estimate the fair value of our principal amount of long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements. (5) Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates. The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at June 30, 2016 are summarized as follows: Contingent Consideration Balance at March 31, 2016 $ 5,886 Additions — Payments — Foreign currency translation adjustments (1) 70 Balance at June 30, 2016 $ 5,956 (1) Reported in other comprehensive income (loss) . Information regarding our investments is as follows: Investments at June 30, 2016 and March 31, 2016 Cost Unrealized Gains Unrealized Losses (2) Fair Value June 30 March 31 June 30 March 31 June 30 March 31 June 30 March 31 Available-for-sale securities: Marketable equity securities (1) $ 9,245 $ 4,681 $ — $ — $ (721 ) $ (185 ) $ 8,524 $ 4,496 Mutual funds 1,206 1,289 418 407 — — 1,624 1,696 Total available-for-sale securities $ 10,451 $ 5,970 $ 418 $ 407 $ (721 ) $ (185 ) $ 10,148 $ 6,192 (1) Our marketable equity securities have been in a unrealized loss position for less than 12 months. (2) Amounts reported include the impact of foreign currency movements relative to the U.S. dollar.

Reclassifications out of Accumu

Reclassifications out of Accumulated Other Comprehensive Income (Notes)	3 Months Ended
	Jun. 30, 2016
Reclassifications out of AOCI [Abstract]
Comprehensive Income (Loss) Note [Text Block]	Reclassifications Out of Accumulated Other Comprehensive Income (Loss) Amounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Foreign Currency Translation is not adjusted for income taxes. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three months ended June 30, 2016 were as follows: Gain (Loss) on Available for Sale Securities (1) Defined Benefit Plans (2) Foreign Currency Translation (3) Total Accumulated Other Comprehensive Income Balance at March 31, 2016 $ (673 ) $ 5,108 $ (72,594 ) $ (68,159 ) Other Comprehensive Income (Loss) before reclassifications (148 ) 103 (17,049 ) (17,094 ) Amounts reclassified from Accumulated Other Comprehensive Income (Loss) 28 (493 ) — (465 ) Net current-period Other Comprehensive Income (Loss) (120 ) (390 ) (17,049 ) (17,559 ) Balance at June 30, 2016 $ (793 ) $ 4,718 $ (89,643 ) $ (85,718 ) Details of amounts reclassified from Accumulated Other Comprehensive Income (Loss) are as follows: (1) Realized gain (loss) on available for sale securities is reported in the interest income and miscellaneous expense line of the Consolidated Statements of Income. (2) Amortization (gain) of defined benefit pension items is reported in the selling, general and administrative expense line of the Consolidated Statements of Income. (3) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Business Acquisitions (Notes)

Business Acquisitions (Notes)	3 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	Business Acquisitions Synergy Health plc On November 2, 2015, STERIS acquired all outstanding shares of Synergy in a cash and stock transaction valued at £24.80 ( $38.17 ) per Synergy share, or a total of approximately $2.3 billion based on the low trading price of Old STERIS’s stock of $73.02 per share on November 2, 2015. Total costs of approximately $200 before tax were incurred during the first three months of fiscal year 2017 related to the Combination and are reported in selling, general and administrative expense. Total consideration for the transaction is presented in the table below. At the closing date of the Combination, vested share option awards remained outstanding under Synergy's Save As You Earn Plans ("SAYE"). In accordance with the provisions of SAYE, vested option awards may be exercised to the extent that the exercise price funds have been accumulated in accordance with the option holder's savings contract. The number of Synergy shares that are expected to be issued have been fair valued based on the same cash and stock consideration available to other Synergy shareholders at the time of the Combination. Cash consideration $ 402,494 STERIS plc shares (25,848,798 ordinary shares issued) 1,887,479 Fair value of consideration available to vested Synergy share option holders 4,819 Total purchase consideration $ 2,294,792 The acquisition of Synergy has been accounted for using the acquisition method of accounting which requires, among other things, the assets acquired, liabilities assumed and noncontrolling interests be recognized at their respective fair values as of the acquisition date. Acquisition accounting is dependent upon certain valuations and other studies that are in progress and are not yet to a stage where there is sufficient information for a definitive measurement. The process for estimating the fair values of identifiable intangible assets and certain tangible assets and assumed liabilities requires the use of judgment in determining the appropriate assumptions and estimates. The purchase price allocation for Synergy is preliminary. As we finalize the fair values of assets acquired, liabilities assumed, and noncontrolling interests, additional purchase price adjustments will be recorded during the measurement period. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact our results of operations. The finalization of the purchase accounting assessment will result in changes in the valuation of assets acquired and liabilities assumed and may have a material impact on the our results of operations and financial position. Goodwill will be allocated to the Healthcare Products, Healthcare Specialty Services, and Applied Sterilization Technologies segments. Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce, which are further described above. Goodwill recognized as a result of the acquisition is not deductible for tax purposes.

Subsequent Events

Subsequent Events	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Schedule of Subsequent Events [Text Block]	Subsequent Events On July 1, 2016 we sold our UK Linen Management Services business to STAR Mayan Limited for approximately £50.0 million. For fiscal year 2017, the UK Linen Management Services business was expected to generate approximately £40.0 million in revenue. The UK Linen Management Services business was part of our Healthcare Specialty Services segment. On July 22, 2016 we acquired Medisafe Holdings Ltd, a U.K. manufacturer of washer/disinfector equipment and related consumables and services for approximately £27.0 million. On an annual basis, the Medisafe product line generates approximately £14.0 million in revenue. The acquisition of Medisafe provides washer manufacturing and research and development in the U.K., and Medisafe's products and services complement our Healthcare product offering. Medisafe will be integrated into our Healthcare Product segment.

Nature of Operations and Summ26

Nature of Operations and Summary of Significant Accounting Policies Accounting Policies (Policies)	3 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation
Use of Estimates, Policy [Policy Text Block]	Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three month period ended June 30, 2016 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2017 .
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Standards Impacting the Company Recently issued accounting standards impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have recently been adopted ASU 2015-05, "Goodwill and other-Internal-Use Software" (Subtopic 350-40) April 2015 The standard provides guidance on a customer's accounting for fees paid in cloud computing arrangements. Previously, there was no U.S. GAAP guidance on accounting for such fees from the customer's perspective. Under the standard, customers will apply the same criteria as vendors to determine whether the arrangement contains a software license or is solely a service contract. The determination could impact the classification of advance payments in the statements of financial position and cash flows as well as the classification of the expenses in the results of operations. The standard is effective for annual periods beginning after December 15, 2015 and interim periods within that period. Early adoption is permitted. First Quarter Fiscal 2017 The adoption of this standard did not have a material impact on our statements of consolidated financial position, results of operations and cash flows. ASU 2016-09, "Stock Compensation: Improvements to Employee Share-Based Payment Accounting" (Topic 718) March 2016 The update simplifies several aspects of the accounting for share-based payment award transactions, including income tax consequences, the classification of awards as either equity or liabilities, and the classification on the statement of cash flows. The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that period. Early adoption is permitted. First Quarter Fiscal 2017 As a result of the adoption of this standard, we recorded $2.4 million of excess tax benefits associated with share based compensation in the statement of income for the three months ended June 30, 2016 and have included the associated cash flows as cash provided by operating activities. Prior periods have not been restated. Standards that have yet to be adopted ASU 2014-09, "Revenue from Contracts with Customers" May 2014 The standard will replace existing revenue recognition standards and significantly expand the disclosure requirements for revenue arrangements. It may be adopted either retrospectively or on a modified retrospective basis to new contracts and existing contracts with remaining performance obligations as of the effective date. The standard update is effective for annual periods beginning after December 15, 2017 and interim periods within that period, early adoption is not permitted before the original public entity effective date of December 15, 2016. N/A We are currently in the process of evaluating the impact that the standard will have on our consolidated financial position, results of operations and cash flows. ASU 2016-02, "Leases" (Topic 842) February 2016 The update will require lessees to record all leases, whether finance or operating, on the balance sheet. An asset will be recorded to represent the right to use the leased asset, and a liability will be recorded to represent the lease obligation. The standard is effective for annual periods beginning after December 15, 2018 and interim periods within that period. Early adoption is permitted. N/A We are in the process of evaluating the impact that the standard will have on our statements of consolidated financial position, results of operations and cash flows. ASU 2016-07, "Investments - Equity Method and Joint Ventures, Simplifying the Transition to the Equity Method of Accounting" (Topic 323) March 2016 The update replaces the previous requirement to retroactively adopt the equity method. The new standard requires that the equity method investor add the cost of acquiring the additional interest in the investee to the current basis of the investor's previously held interest and adopt the equity method of accounting as of the date the investment becomes qualified for equity method accounting. The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that period. Early adoption is permitted. N/A We do not expect the adoption of this standard to have a material impact on our statements of consolidated financial position, results of operations and cash flows.

Restructuring Liabilities relat

Restructuring Liabilities related to restructuring (Tables)	3 Months Ended
	Jun. 30, 2016
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	iabilities related to restructuring activities were $688 and $700 at June 30, 2016 and March 31, 2016, respectively and are recorded as current liabilities on the accompanying Consolidated Balance Sheets within “Accrued payroll and other related liabilities” and “Accrued expenses and other.”
Schedule of Restructuring and Related Costs [Table Text Block]	The following table summarizes our total pre-tax restructuring expenses for the first quarters of fiscal 2017 and fiscal 2016: Three Months Ended June 30, 2016 Fiscal 2014 Restructuring Plan Lease termination obligation and other $ 154 Total restructuring charges $ 154 Three Months Ended June 30, 2015 Fiscal 2014 Restructuring Plan (1) Severance and other compensation related costs $ (806 ) Lease termination obligation and other 80 Product rationalization 277 Total restructuring benefit $ (449 ) (1) Includes $277 in expense recorded to cost of revenues on Consolidated Statements of Income.

Property, Plant and Equipment L

Property, Plant and Equipment Level 3 (Tables)	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Property, Plant and Equipment [Table Text Block]	Information related to the major categories of our depreciable assets is as follows: June 30, March 31, Land and land improvements (1) $ 39,054 $ 39,051 Buildings and leasehold improvements 443,234 446,277 Machinery and equipment 574,277 580,962 Linens 42,291 42,354 Information systems 131,487 126,180 Radioisotope 434,189 434,152 Construction in progress (1) 89,692 79,291 Total property, plant, and equipment 1,754,224 1,748,267 Less: accumulated depreciation and depletion (698,518 ) (683,948 ) Property, plant, and equipment, net $ 1,055,706 $ 1,064,319 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.
Schedule of Change in Asset Retirement Obligation [Table Text Block]	.

Inventories, Net Level 3 (Table

Inventories, Net Level 3 (Tables)	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory costs include material, labor, and overhead. Inventories, net consisted of the following: June 30, March 31, Raw materials $ 67,374 $ 62,673 Work in process 22,192 19,614 Finished goods 156,236 146,820 LIFO reserve (17,270 ) (17,608 ) Reserve for excess and obsolete inventory (18,887 ) (18,707 ) Inventories, net $ 209,645 $ 192,792

Debt Level 3 (Tables)

Debt Level 3 (Tables)	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Schedule of Debt [Table Text Block]	Indebtedness was as follows: June 30, March 31, Private Placement $ 666,000 $ 666,000 Deferred financing costs (3,299 ) (3,420 ) Credit Agreement 889,137 905,216 Total long term debt $ 1,551,838 $ 1,567,796

Additional Consolidated Balan31

Additional Consolidated Balance Sheets Information Level 3 (Tables)	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Additional information related to our Consolidated Balance Sheets is as follows: June 30, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 37,685 $ 30,175 Accrued vacation/paid time off 12,070 14,368 Accrued bonuses 8,679 31,502 Accrued employee commissions 8,727 13,809 Other postretirement benefit obligations-current portion 2,463 2,463 Other employee benefit plans obligations-current portion 899 1,659 Total accrued payroll and other related liabilities $ 70,523 $ 93,976 Accrued expenses and other: Deferred revenues $ 64,205 $ 56,238 Self-insured risk reserves-current portion 8,294 8,266 Accrued dealer commissions 13,982 12,717 Accrued warranty 5,856 5,909 Other 58,465 70,245 Total accrued expenses and other $ 150,802 $ 153,375 Other liabilities: Self-insured risk reserves-long-term portion $ 13,257 $ 13,257 Other postretirement benefit obligations-long-term portion 15,621 15,932 Defined benefit pension plans obligations-long-term portion 23,221 25,301 Other employee benefit plans obligations-long-term portion 4,186 4,366 Asset retirement obligation-long-term portion 10,059 10,342 Other 16,112 15,100 Total other liabilities $ 82,456 $ 84,298

Benefit Plans Level 3 (Tables)

Benefit Plans Level 3 (Tables)	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Schedule of Defined Benefit Plans Disclosures [Table Text Block]	Components of the net periodic benefit cost for our defined benefit pension plans and other postretirement medical benefits plan were as follows: AMSCO Plan Other Defined Benefit Pension Plan Other Postretirement Benefits Plan Three Months Ended June 30, 2016 2015 2016 2015 2016 2015 Service cost $ — $ 16 $ 472 $ — $ — $ — Interest cost — 336 189 — 139 148 Expected return on plan assets — (605 ) — — — — Amortization of loss — 361 — — 184 207 Amortization of prior service cost — — — — (816 ) (815 ) Net periodic benefit cost $ — $ 108 $ 661 $ — $ (493 ) $ (460 )

Business Segment Information Le

Business Segment Information Level 3 (Tables)	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Financial information for each of our segments is presented in the following tables: Three Months Ended June 30, 2016 2015 Revenues: Healthcare Products $ 281,298 $ 261,086 Healthcare Specialty Services 157,888 68,241 Life Sciences 81,189 56,772 Applied Sterilization Technologies 116,573 53,689 Corporate and other 1,430 114 Total revenues $ 638,378 $ 439,902 Segment operating income: Healthcare Products $ 34,637 $ 29,350 Healthcare Specialty Services 3,318 3,900 Life Sciences 24,462 13,450 Applied Sterilization Technologies 39,603 16,543 Corporate and other (496 ) (1,898 ) Total segment operating income $ 101,524 $ 61,345 Less: Adjustments Restructuring charges (1) $ 154 $ (449 ) Amortization of acquired intangible assets (2) 19,529 6,021 Acquisition, divestiture and integration related charges (3) 5,233 11,546 Amortization of inventory and property "step up" to fair value (2) 3,086 11 Total operating income $ 73,522 $ 44,216

Common Shares Level 3 (Tables)

Common Shares Level 3 (Tables)	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Schedule of Weighted Average Number of Shares [Table Text Block]	The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share: Three Months Ended June 30, 2016 2015 Denominator (shares in thousands): Weighted average shares outstanding—basic 86,038 59,768 Dilutive effect of share equivalents 481 518 Weighted average shares outstanding and share equivalents—diluted 86,519 60,286
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Three Months Ended June 30, 2016 2015 (shares in thousands) Number of share options 364 52

Share-Based Compensation Level

Share-Based Compensation Level 3 (Tables)	3 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Assumptions Used	The following weighted-average assumptions were used for options granted during the first three months of fiscal 2017 and fiscal 2016 : Fiscal 2017 Fiscal 2016 Risk-free interest rate 1.29 % 1.46 % Expected life of options 5.5 years 5.6 years Expected dividend yield of stock 1.55 % 1.40 % Expected volatility of stock 22.78 % 24.74 %
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding	A summary of share option activity is as follows: Number of Options Weighted Average Exercise Price Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at March 31, 2016 1,729,517 $ 44.01 Granted 370,212 69.72 Exercised (18,131 ) 29.95 Forfeited (2,703 ) 59.41 Canceled — — Outstanding at June 30, 2016 2,078,895 $ 48.69 6.7 years $ 42,065 Exercisable at June 30, 2016 1,238,705 $ 38.35 5.2 years $ 37,658
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	A summary of the non-vested restricted share activity is presented below: Number of Restricted Shares Number of Restricted Share Units Weighted-Average Grant Date Fair Value Non-vested at March 31, 2016 872,972 41,641 $ 51.98 Granted 219,167 9,390 69.77 Vested (186,856 ) (10,589 ) 38.74 Canceled (10,722 ) (2,275 ) 60.54 Non-vested at June 30, 2016 894,561 38,167 $ 59.02

Financial and Other Guarantees

Financial and Other Guarantees Level 3 (Tables)	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Schedule of Guarantor Obligations [Table Text Block]	Changes in our warranty liability during the first three months of fiscal 2017 were as follows: Balance, March 31, 2016 $ 5,909 Warranties issued during the period 2,742 Settlements made during the period (2,795 ) Balance, June 30, 2016 $ 5,856

Forward and Swap Contracts Leve

Forward and Swap Contracts Level 3 (Tables)	3 Months Ended
	Jun. 30, 2016
Notes To Financial Statements [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	Asset Derivatives Liability Derivatives Balance Sheet Fair Value at Fair Value at Fair Value at Fair Value at Location June 30, 2016 March 31, 2016 June 30, 2016 March 31, 2016 Prepaid & Other $ 351 $ 145 $ — $ — Accrued expenses and other $ — $ — $ 293 $ 122
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income: Location of gain (loss) recognized in income Amount of gain (loss) recognized in income Three Months Ended June 30, 2016 2015 Foreign currency forward contracts Selling, general and administrative $ (1,019 ) $ 432 Commodity swap contracts Cost of revenues $ 211 $ (45 )

Fair Value Measurements Level 3

Fair Value Measurements Level 3 (Tables)	3 Months Ended
	Jun. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following table shows the fair value of our financial assets and liabilities at June 30, 2016 and March 31, 2016: Fair Value Measurements at June 30, 2016 and March 31, 2016 Using Carrying Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Level 1 Level 2 Level 3 June 30 March 31 June 30 March 31 June 30 March 31 June 30 March 31 Assets: Cash and cash equivalents (1) $ 242,423 $ 248,841 $ 217,246 $ 225,090 $ 25,177 $ 23,751 $ — $ — Forward and swap contracts (2) 351 145 — — 351 145 — — Investments (3) 10,148 6,192 10,148 6,192 — — — — Liabilities: Forward and swap contracts (2) $ 293 $ 122 $ — $ — $ 293 $ 122 $ — $ — Deferred compensation plans (3) 1,703 1,765 1,703 1,765 — — — — Long term debt (4) 1,551,838 1,567,796 — — 1,601,514 1,592,184 — — Contingent consideration obligations (5) 5,956 5,886 — — — — 5,956 5,886 (1) Money market fund holdings are classified as level two as active market quoted prices are not available. (2) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (3) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Changes in the value of the investment accounts are recognized each period based on the fair value of the underlying investments. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers including an incremental investment of $4,564 made in April 2016. Changes in the value of the investment are recognized each period based on the fair value of the investment. (4) We estimate the fair value of our principal amount of long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements. (5) Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.
Schedule of Level 3 Contingent Consideration [Table Text Block]	The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at June 30, 2016 are summarized as follows: Contingent Consideration Balance at March 31, 2016 $ 5,886 Additions — Payments — Foreign currency translation adjustments (1) 70 Balance at June 30, 2016 $ 5,956 (1) Reported in other comprehensive income (loss) . Information regarding our investments is as follows: Investments at June 30, 2016 and March 31, 2016 Cost Unrealized Gains Unrealized Losses (2) Fair Value June 30 March 31 June 30 March 31 June 30 March 31 June 30 March 31 Available-for-sale securities: Marketable equity securities (1) $ 9,245 $ 4,681 $ — $ — $ (721 ) $ (185 ) $ 8,524 $ 4,496 Mutual funds 1,206 1,289 418 407 — — 1,624 1,696 Total available-for-sale securities $ 10,451 $ 5,970 $ 418 $ 407 $ (721 ) $ (185 ) $ 10,148 $ 6,192 (1) Our marketable equity securities have been in a unrealized loss position for less than 12 months. (2) Amounts reported include the impact of foreign currency movements relative to the U.S. dollar.
Unrealized Gain (Loss) on Investments [Table Text Block]	Information regarding our investments is as follows: Investments at June 30, 2016 and March 31, 2016 Cost Unrealized Gains Unrealized Losses (2) Fair Value June 30 March 31 June 30 March 31 June 30 March 31 June 30 March 31 Available-for-sale securities: Marketable equity securities (1) $ 9,245 $ 4,681 $ — $ — $ (721 ) $ (185 ) $ 8,524 $ 4,496 Mutual funds 1,206 1,289 418 407 — — 1,624 1,696 Total available-for-sale securities $ 10,451 $ 5,970 $ 418 $ 407 $ (721 ) $ (185 ) $ 10,148 $ 6,192

Reclassifications out of Accu39

Reclassifications out of Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Jun. 30, 2016
Reclassifications out of AOCI [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three months ended June 30, 2016 were as follows: Gain (Loss) on Available for Sale Securities (1) Defined Benefit Plans (2) Foreign Currency Translation (3) Total Accumulated Other Comprehensive Income Balance at March 31, 2016 $ (673 ) $ 5,108 $ (72,594 ) $ (68,159 ) Other Comprehensive Income (Loss) before reclassifications (148 ) 103 (17,049 ) (17,094 ) Amounts reclassified from Accumulated Other Comprehensive Income (Loss) 28 (493 ) — (465 ) Net current-period Other Comprehensive Income (Loss) (120 ) (390 ) (17,049 ) (17,559 ) Balance at June 30, 2016 $ (793 ) $ 4,718 $ (89,643 ) $ (85,718 ) Details of amounts reclassified from Accumulated Other Comprehensive Income (Loss) are as follows: (1) Realized gain (loss) on available for sale securities is reported in the interest income and miscellaneous expense line of the Consolidated Statements of Income. (2) Amortization (gain) of defined benefit pension items is reported in the selling, general and administrative expense line of the Consolidated Statements of Income. (3) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Business Acquisitions (Tables)

Business Acquisitions (Tables)	3 Months Ended
	Jun. 30, 2016
Business Acquisition [Line Items]
Business Combination With Synergy Total Consideration [Table Text Block]	Cash consideration $ 402,494 STERIS plc shares (25,848,798 ordinary shares issued) 1,887,479 Fair value of consideration available to vested Synergy share option holders 4,819 Total purchase consideration $ 2,294,792

Nature of Operations and Summ41

Nature of Operations and Summary of Significant Accounting Policies Level 4 (Details)	3 Months Ended
	Jun. 30, 2016USD ($)
Loss Contingencies [Line Items]
Proceeds and Excess Tax Benefit from Share-based Compensation	$ 2,400,000

Restructuring Restructuring res

Restructuring Restructuring reserves and related costs (Details) - USD ($)		3 Months Ended
		Jun. 30, 2016	Jun. 30, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		$ 154,000	$ (449,000)
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning of Period		700,000
Restructuring Reserve, End of Period		688,000
FY 2014 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date		19,128,000
Operating Expense [Member] | FY 2014 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		154,000	(449,000)
Operating Expense [Member] | FY 2014 Restructuring Plan [Member] | Severance and termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			(806,000)
Operating Expense [Member] | FY 2014 Restructuring Plan [Member] | Product [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	[1]		277,000
Operating Expense [Member] | FY 2014 Restructuring Plan [Member] | Lease termination obligations
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		154,000	80,000
Restructuring expenses | FY 2014 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date		11,032,000
Cost of revenues | FY 2014 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			$ 277,000
Restructuring and Related Cost, Cost Incurred to Date		8,096,000
Healthcare Products [Member] [Member] | FY 2014 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date		15,726,000
Healthcare Specialty Services [Member] | FY 2014 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date		1,293,000
Life Science Member [Member] | FY 2014 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date		829,000
Applied Sterilization Technologies [Member] | FY 2014 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date		$ 1,280,000
[1]	(1) Includes $277 in expense recorded to cost of revenues on Consolidated Statements of Income.

Property, Plant and Equipment43

Property, Plant and Equipment Level 4 (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Mar. 31, 2016
Property, Plant and Equipment [Line Items]
Land	$ 39,054	$ 39,051
Buildings and Improvements, Gross	443,234	446,277
Machinery and Equipment, Gross	574,277	580,962
Linen	42,291	42,354
Capitalized Computer Software, Gross	131,487	126,180
Materials, Supplies, and Other	434,189	434,152
Construction in Progress, Gross	89,692	79,291
Property, Plant and Equipment, Gross	1,754,224	1,748,267
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(698,518)	(683,948)
Property, Plant and Equipment, Net	$ 1,055,706	$ 1,064,319

Inventories, Net Level 4 (Detai

Inventories, Net Level 4 (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Mar. 31, 2016
Inventory, Raw Materials	$ 67,374	$ 62,673
Inventory, Work in Process	22,192	19,614
Inventory, Finished Goods	156,236	146,820
Inventory, LIFO Reserve	(17,270)	(17,608)
Inventory Valuation Reserves	(18,887)	(18,707)
Inventory, Net	$ 209,645	$ 192,792

Debt Level 4 (Details)

Debt Level 4 (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2016
Debt Instrument [Line Items]
Proceeds from Issuance of Private Placement	$ 0	$ 350,000
Debt Instrument, Face Amount	666,000		$ 666,000
Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Net	(3,299)		(3,420)
Line of Credit Facility, Amount Outstanding	889,137		905,216
Long-term Debt	$ 1,551,838		$ 1,567,796

Additional Consolidated Balan46

Additional Consolidated Balance Sheets Information Level 4 (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Mar. 31, 2016
Employee-related Liabilities	$ 37,685	$ 30,175
Accrued Vacation	12,070	14,368
Accrued Bonuses	8,679	31,502
Accrued Liabilities for Commissions, Expense and Taxes	8,727	13,809
Other Postretirement Benefits Payable	2,463	2,463
Pension and Other Postretirement and Postemployment Benefit Plans, Liabilities	899	1,659
Employee-related Liabilities, Current	70,523	93,976
Deferred Revenue	64,205	56,238
Self Insurance Reserve, Current	8,294	8,266
Accrued Sales Commission	13,982	12,717
Product Warranty Accrual	5,856	5,909
Accrued Liabilities	150,802	153,375
Self Insurance Reserve, Noncurrent	13,257	13,257
Other Postretirement Benefits Payable, Noncurrent	15,621	15,932
Defined Benefit Pension Plan, Liabilities, Noncurrent	23,221	25,301
Pension and Other Postretirement and Postemployment Benefit Plans, Liabilities, Noncurrent	4,186	4,366
Asset Retirement Obligations, Noncurrent	10,059	10,342
Other Liabilities	16,112	15,100
Other Accrued Liabilities	58,465	70,245
Other Liabilities, Noncurrent	$ 82,456	$ 84,298

Income Tax Expense Unrecognized

Income Tax Expense Unrecognized Tax Benefits (Details)	3 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Effective Income Tax Rate, Continuing Operations	22.60%	37.00%

Benefit Plans Level 4 (Details)

Benefit Plans Level 4 (Details) - USD ($)	Aug. 26, 2015	Jun. 30, 2016	Jun. 30, 2015	Aug. 19, 2015	Sep. 30, 2008
Defined Benefit Plan Disclosure [Line Items]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 4,641,000
Defined Benefit Plan, Accumulated Benefit Obligation					$ 46,001,000
DBP Purchase Price of Annuity Contract				$ 51,805,000
United States Pension Plans of US Entity, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost		$ 0	$ 16,000
Defined Benefit Plan, Interest Cost		0	336,000
Defined Benefit Plan, Expected Return on Plan Assets		0	(605,000)
Defined Benefit Plan, Amortization of Gains (Losses)		0	361,000
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)		0	0
Defined Benefit Plan, Net Periodic Benefit Cost		0	108,000
Other Defined Benefit Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost		472,000	0
Defined Benefit Plan, Interest Cost		189,000	0
Defined Benefit Plan, Expected Return on Plan Assets		0	0
Defined Benefit Plan, Amortization of Gains (Losses)		0	0
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)		0	0
Defined Benefit Plan, Net Periodic Benefit Cost		661,000	0
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost		0	0
Defined Benefit Plan, Interest Cost		139,000	148,000
Defined Benefit Plan, Expected Return on Plan Assets		0	0
Defined Benefit Plan, Amortization of Gains (Losses)		184,000	207,000
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)		(816,000)	(815,000)
Defined Benefit Plan, Net Periodic Benefit Cost		$ (493,000)	$ (460,000)

Business Segment Information 49

Business Segment Information Level 4 (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2016
Segment Reporting Information [Line Items]
Assets	$ 5,293,171		$ 5,346,416
Revenues	638,378	$ 439,902
Operating Income (Loss)	73,522	44,216
Restructuring Charges	154	(449)
amortization and impairment of acquired intangible assets	19,529	6,021
acquisition and integration related charges	5,233	11,546
amortization of inventory and property step up to fair value	3,086	11
Defined Benefit Plan, Settlements, Benefit Obligation			$ 26,470
Healthcare Products [Member] [Member]
Segment Reporting Information [Line Items]
Revenues	281,298	261,086
Operating Income (Loss)	34,637	29,350
Healthcare Specialty Services [Member]
Segment Reporting Information [Line Items]
Revenues	157,888	68,241
Operating Income (Loss)	3,318	3,900
Life Science Member [Member]
Segment Reporting Information [Line Items]
Revenues	81,189	56,772
Operating Income (Loss)	24,462	13,450
Applied Sterilization Technologies [Member]
Segment Reporting Information [Line Items]
Revenues	116,573	53,689
Operating Income (Loss)	39,603	16,543
OperatingSegmentCorpandOther [Member]
Segment Reporting Information [Line Items]
Revenues	1,430	114
Operating Income (Loss)	(496)	(1,898)
OperatingSegmentAll [Member]
Segment Reporting Information [Line Items]
Revenues	638,378	439,902
Operating Income (Loss)	$ 101,524	$ 61,345

Common Shares Level 4 (Details)

Common Shares Level 4 (Details) shares in Thousands	3 Months Ended
	Jun. 30, 2016$ / sharesshares	Jun. 30, 2015shares	Mar. 31, 2016$ / shares	Dec. 31, 2015£ / shares
Weighted Average Common Shares Outstanding Basic and Diluted [Line Items]
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 0.10		$ 0.15
Weighted Average Number of Shares Outstanding, Basic	86,038	59,768
Weighted Average Number Diluted Shares Outstanding Adjustment	481	518
Weighted Average Number of Shares Outstanding, Diluted	86,519	60,286
United Kingdom, Pounds
Weighted Average Common Shares Outstanding Basic and Diluted [Line Items]
Preferred Stock, Par or Stated Value Per Share | £ / shares				£ 0.10

Common Shares Common share opti

Common Shares Common share options (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Jun. 30, 2016USD ($)$ / sharesshares	Mar. 31, 2016USD ($)$ / sharesshares	Jun. 30, 2015shares	Dec. 31, 2015£ / shares	Dec. 31, 2015USD ($)$ / sharesshares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Preferred Stock, Shares Issued | shares	100,000	100,000			100,000
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 0.10	$ 0.15
Preferred Stock, Value, Issued | $	$ 15	$ 15
Preferred Stock, Dividend Rate, Percentage		5.00%
Preferred Stock, Redemption Price Per Share | (per share)				£ 0.10	$ 0.15
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares	364,000		52,000
United States of America, Dollars
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Preferred Stock, Par or Stated Value Per Share | $ / shares					$ 0.15
Preferred Stock, Value, Issued | $					$ 15

Repurchases of Common Shares Le

Repurchases of Common Shares Level 4 (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Treasury Stock, Shares, Acquired	0		0
Payments for Repurchase of Common Stock	$ 5,171	$ 9,573
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	104,626

Share-Based Compensation Leve53

Share-Based Compensation Level 4 (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Item]
Remaining shares available for grant	1,613,977
Weighted-average assumptions used for options granted:
Risk-free interest rate	1.29%	1.46%
Expected life of options	5 years 6 months	5 years 7 months 7 days
Exptected dividend yield of stock	1.55%	1.40%
Expected volatility of stock	22.78%	24.74%
Estimated forfeiture rate	1.85%	1.55%
Summary of share option activity:
Number of Options, Outstanding, Beginning of Period	1,729,517
Weighted Average Exercise Price, Outstanding, Beginning of Period	$ 44.01
Number of Options, Granted	370,212
Weighted Average Exercise Price, Granted	$ 69.72
Number of Options, Exercised	(18,131)
Weighted Average Exercise Price, Exercised	$ 29.95
Number of Options, Forfeited	(2,703)
Weighted Average Exercise Price, Forfeited	$ 59.41
Number of Options, Canceled	0
Weighted Average Exercise Price, Canceled	$ 0
Number of Options, Outstanding, End of Period	2,078,895
Weighted Average Exercise Price, Outstanding, End of Period	$ 48.69
Average Remaining Contractual Term, Outstanding	6 years 8 months
Aggregate Intrinsic Value, Outstanding	$ 42,065
Number of Options, Exercisable	1,238,705
Weighted Average Exercise Price, Exercisable	$ 38.35
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	5 years 2 months 6 days
Aggregate Intrinsic Value, Exercisable	$ 37,658
Non-vested stock options outstanding expected to vest	816,670
Common Stock, Fair Market Value Per Share	$ 68.75
Total intrinsic value of stock options exercised	$ 727	$ 5,582
Net cash proceeds from the exercise of stock options	758	4,881
Tax benefit from stock option exercises	$ 2,440	$ 3,910
Weighted average grant date fair value of stock option grants, per share	$ 13.15	$ 14.11
Summary of non-vested restricted share activity:
Unrecognized compensation cost related to nonvested share-based compensation granted	$ 47,882
Weighted average period for recognition of unrecognized compensation cost	2 years 5 months 12 days
Stock Appreciation Rights (SARs) [Member]
Summary of non-vested restricted share activity:
FairValueOfOutstandingStockAppreciationRights	$ 1,857	$ 1,966
Restricted Stock
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	872,972
Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period	$ 51.98
Number of Restricted Shares, Granted	219,167
Weighted-Average Grant Date Fair Value, Granted	$ 69.77
Number of Restricted Shares, Vested	(186,856)
Weighted-Average Grant Date Fair Value, Vested	$ 38.74
Number of Restricted Shares, Canceled	(10,722)
Weighted-Average Grant Date Fair Value, Canceled	$ 60.54
Number of Restricted Shares, Non-vested at End of Period	894,561
Weighted-Average Grant Date Fair Value, Non-vested at End of Period	$ 59.02
Fair Value, Share-based Payment Awards, Other than Options	$ 7,087
Restricted Stock Units (RSUs)
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	41,641
Number of Restricted Shares, Granted	9,390
Number of Restricted Shares, Vested	(10,589)
Number of Restricted Shares, Canceled	(2,275)
Number of Restricted Shares, Non-vested at End of Period	38,167

Financial and Other Guarantee54

Financial and Other Guarantees Level 4 (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Guarantor Obligations [Line Items]
Deferred Service Revenue	$ 32,953	$ 33,416
Product Warranty Accrual	5,856	$ 5,909
Product Warranty Accrual, Warranties Issued	2,742
Standard Product Warranty Accrual, Payments	$ (2,795)

Forward and Swap Contracts Le55

Forward and Swap Contracts Level 4 (Details) £ in Thousands, lb in Thousands, MXN in Thousands, CAD in Thousands, $ in Thousands	3 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016GBP (£)lb	Jun. 30, 2016USD ($)lb	Jun. 30, 2016CADlb	Jun. 30, 2016MXNlb	Mar. 31, 2016USD ($)
Derivative [Line Items]
Non-derivative Net Investment Hedge				$ 123,811
Other Assets [Member]
Derivative [Line Items]
Derivative Assets				351			$ 145
Derivative Liabilities				0			0
Accrued Liabilities [Member]
Derivative [Line Items]
Derivative Assets				0			0
Derivative Liabilities				$ 293			$ 122
Selling, General and Administrative Expenses [Member]
Derivative [Line Items]
Foreign Currency Transaction Gain, before Tax	$ (1,019)	$ (432)
Cost of Sales [Member]
Derivative [Line Items]
Gain (Loss) on Sale of Commodity Contracts	$ 211	$ (45)
212234 Copper Ore and Nickel Ore Mining [Member]
Derivative [Line Items]
Investment Contract Weight | lb			499	499	499	499
Mexico, Pesos
Derivative [Line Items]
Derivative Liability, Notional Amount | MXN						MXN 90,000
Canada, Dollars
Derivative [Line Items]
Derivative Liability, Notional Amount | CAD					CAD 8,000
Euro Member Countries, Euro
Derivative [Line Items]
Derivative Liability, Notional Amount | £			£ 3,500

Fair Value Measurements Level 4

Fair Value Measurements Level 4 (Details) £ in Thousands, MXN in Thousands		3 Months Ended
		Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016GBP (£)	Jun. 30, 2016USD ($)		Jun. 30, 2016MXN	Mar. 31, 2016USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Payments to Acquire Investments		$ 4,564,000	$ 0
Available-for-sale Securities, Amortized Cost Basis					$ 10,451,000			$ 5,970,000
Investments, Fair Value Disclosure					10,148,000			6,192,000
Business Combination, Contingent Consideration, Liability					5,956,000			5,886,000
Unrealized Gain on AFS Securities	[1]				418,000			407,000
Unrealized Loss on AFS Securities	[1]				(721,000)			(185,000)
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[2]				217,246,000			225,090,000
Foreign Currency Contract, Asset, Fair Value Disclosure	[3]				0			0
Foreign Currency Contracts, Liability, Fair Value Disclosure	[3]				0			0
Investments, Fair Value Disclosure	[4]				10,148,000			6,192,000
Deferred Compensation Plan Assets, Fair Value	[4]				1,703,000			1,765,000
Long-term Debt, Fair Value	[5]				0			0
Business Combination, Contingent Consideration, Liability					0	[6]		0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[2]				25,177,000			23,751,000
Foreign Currency Contract, Asset, Fair Value Disclosure	[3]				351,000			145,000
Foreign Currency Contracts, Liability, Fair Value Disclosure	[3]				293,000			122,000
Investments, Fair Value Disclosure					0	[4]		0
Deferred Compensation Plan Assets, Fair Value					0	[4]		0
Long-term Debt, Fair Value	[5]				1,601,514,000			1,592,184,000
Business Combination, Contingent Consideration, Liability					0	[6]		0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure					0			0
Foreign Currency Contract, Asset, Fair Value Disclosure					0	[3]		0
Foreign Currency Contracts, Liability, Fair Value Disclosure					0	[3]		0
Investments, Fair Value Disclosure					0	[4]		0
Deferred Compensation Plan Assets, Fair Value					0	[4]		0
Long-term Debt, Fair Value	[5]				0			0
Business Combination, Contingent Consideration, Liability	[6]				5,956,000			5,886,000
Capital Additions [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		0
Reductions and Payout [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		0
Foreign Currency Gain (Loss) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		70,000
Cost of Sales [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Gain (Loss) on Sale of Commodity Contracts		$ 211,000	$ (45,000)
United Kingdom, Pounds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability, Notional Amount | £				£ 4,000
Euro Member Countries, Euro
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability, Notional Amount | £				£ 3,500
Switzerland, Francs
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability, Notional Amount | MXN							MXN 90,000
Equity Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities, Amortized Cost Basis					9,245,000			4,681,000
Investments, Fair Value Disclosure					8,524,000			4,496,000
Unrealized Gain on AFS Securities	[1]				0			0
Unrealized Loss on AFS Securities	[1]				(721,000)			(185,000)
Mutual Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities, Amortized Cost Basis					1,206,000			1,289,000
Investments, Fair Value Disclosure					1,624,000			1,696,000
Unrealized Gain on AFS Securities	[1]				418,000			407,000
Unrealized Loss on AFS Securities	[1]				0			0
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[2]				242,423,000			248,841,000
Foreign Currency Contract, Asset, Fair Value Disclosure	[3]				351,000			145,000
Foreign Currency Contracts, Liability, Fair Value Disclosure	[3]				293,000			122,000
Investments, Fair Value Disclosure	[4]				10,148,000			6,192,000
Deferred Compensation Plan Assets, Fair Value	[4]				1,703,000			1,765,000
Long-term Debt, Fair Value	[5]				1,551,838,000			1,567,796,000
Business Combination, Contingent Consideration, Liability	[6]				$ 5,956,000			$ 5,886,000
[1]	Amounts reported include the impact of foreign currency movements relative to the U.S. dollar.
[2]	(1) Money market fund holdings are classified as level two as active market quoted prices are not available.
[3]	(2) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.
[4]	We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Changes in the value of the investment accounts are recognized each period based on the fair value of the underlying investments. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers including an incremental investment of $4,564 made in April 2016. Changes in the value of the investment are recognized each period based on the fair value of the investment.
[5]	(4) We estimate the fair value of our principal amount of long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements.
[6]	(5) Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.

Reclassifications out of Accu57

Reclassifications out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2016
Reclassifications from AOCI [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax		$ (85,718)		$ (68,159)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax		(120)	$ (848)
Other Comprehensive Income (Loss), Net of Tax		(17,094)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		(465)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent		(17,559)	$ 12,797
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Reclassifications from AOCI [Line Items]
Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	[1]	(793)		(673)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	[1]	(148)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	[1]	28
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	[1]	(120)
Accumulated Defined Benefit Plans Adjustment [Member]
Reclassifications from AOCI [Line Items]
Accumulated Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net of Tax	[2]	4,718		5,108
Other Comprehensive Income (Loss), Net of Tax	[2]	103
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	[2]	(493)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	[2]	(390)
Accumulated Translation Adjustment [Member]
Reclassifications from AOCI [Line Items]
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax		(89,643)		$ (72,594)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax		(17,049)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent		$ (17,049)
[1]	(1) Realized gain (loss) on available for sale securities is reported in the interest income and miscellaneous expense line of the Consolidated Statements of Income.
[2]	(2) Amortization (gain) of defined benefit pension items is reported in the selling, general and administrative expense line of the Consolidated Statements of Income. (3) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Business Acquisitions (Details)

Business Acquisitions (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Jun. 30, 2016USD ($)	Mar. 31, 2016USD ($)	Nov. 02, 2015£ / shares	Nov. 02, 2015USD ($)$ / sharesshares
Business Acquisition [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares				25,848,798
Synergy Combination Cash Consideration				$ 402,494
Business Combination, Contingent Consideration, Liability	$ 5,956	$ 5,886
Synergy Combination Total Stock Consideration				1,887,479
FV of consideration available to vested Synergy share option holders				$ 4,819
STERIS Closing Stock Price at 11/02/2015 | $ / shares				$ 73.02
Synergy Health plc [Member]
Business Acquisition [Line Items]
Synergy Combination Total Consideration				$ 2,294,792
Approximate purchase price of entity				$ 2,300,000
Business Combination, Acquisition Related Costs	$ 200
United Kingdom, Pounds
Business Acquisition [Line Items]
Value of transaction per Synergy Share | £ / shares			£ 24.80
United States of America, Dollars
Business Acquisition [Line Items]
Value of transaction per Synergy Share | $ / shares				$ 38.17

Subsequent Events Level 4 (Deta

Subsequent Events Level 4 (Details) $ in Thousands	Jul. 01, 2016GBP (£)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Mar. 31, 2017GBP (£)	Mar. 31, 2016GBP (£)	Jul. 22, 2016GBP (£)
Subsequent Event [Line Items]
Proceeds from Sales of Business, Affiliate and Productive Assets	£ 50
Revenues | $		$ 638,378	$ 439,902
Medisafe Holdings, LTD [Member]
Subsequent Event [Line Items]
Revenues					£ 14
Scenario, Forecast [Member]
Subsequent Event [Line Items]
Approximate purchase price of entity						£ 27
Revenues				£ 40